formulation

Rentschler and Leukocare announce strategic alliance and equity investment

pagal

Laupheim and Munich/Martinsried, Germany, February 2, 2017 – Rentschler Biotechnologie GmbH, Laupheim and Leukocare AG, Martinsried today announced a strategic alliance under which Leukocare will become the specialized technology partner and the exclusive formulation developer for Rentschler’s biopharmaceuticals business. Rentschler in return will become the first and only contract development and manufacturing organization (CDMO) to … Skaityti toliau

LEUKOCARE grants license to US vaccine company PaxVax

pagal

LEUKOCARE AG, Germany, and PaxVax, Inc., USA, today announced that both partners have entered into a licensing agreement granting PaxVax access to LEUKOCARE’s proprietary SPS® formulation technology platform for the clinical development and subsequent commercialization of one of PaxVax’s live viral vaccine products. The licensing agreement provides to PaxVax exclusive access to two product-specific pharmaceutical … Skaityti toliau